Renal cell carcinoma
Not recruitingStudy on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment
Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment
- Disease:Renal cell carcinoma
- Substances:AtezolizumabCabozantinib
Poland- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:F. Hoffmann-La Roche AG















